The Citizens Commission on Human Rights (CCHR) is urging consumers to review psychiatric drug labeling for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, even when they are listed as rare. The call follows recent reports of violent crimes in which individuals were allegedly taking or withdrawing from antidepressants, stimulants, or other psychiatric drugs with documented side effects of aggression, homicidal ideation, and suicidal behavior.
CCHR emphasizes that a rare warning buried in a package insert does not substitute for a doctor's direct communication with the patient. Jan Eastgate, president of CCHR International, stated, "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The issue of psychiatrist responsibility is being debated in both courtrooms and professional circles. Psychiatric Times recently published an article titled "Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients' Criminal Behavior?" discussing a high-profile murder case where the defense argued that psychiatric polypharmacy contributed to violent behavior. The journal noted that "a good portion of the public and the media appear to support the defense theory" and that the litigation "places psychiatrists and other mental health providers under scrutiny."
When prescribed drugs are alleged to have induced violent or criminal behavior, one legal doctrine is involuntary intoxication. Its applicability depends on whether the drug was taken as prescribed and whether the person knew or could reasonably have known of the intoxicating or behavioral effect. Eastgate added, "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose. Psychiatrists must disclose what patients need to make informed decisions."
This concern is not new. In a December 2005 article on psychopharmacology liability, Psychiatric Times discussed psychiatrists' duties in light of the FDA's 2004 public health advisory on antidepressants, which identified reports of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania in adults and children. In October 2004, the FDA mandated a boxed warning on suicidality in children and adolescents, later expanded to young adults.
CCHR's compilation of international regulatory warnings shows 57 warnings or safety notices since 2004 involving violence, aggression, or hostility, compared to five in 2004—a 1,040% increase. Thirteen of these specifically reference homicidal ideation or thoughts of harming others.
Drug labeling provides specific examples. Homicidal ideation was added to extended-release venlafaxine labeling in 2005. In 2009, the FDA required a boxed neuropsychiatric warning for bupropion products, citing postmarketing reports of hostility, agitation, aggression, psychosis, homicidal ideation, and suicidal events. In 2023, the FDA mandated class-wide labeling for CNS stimulants warning that "anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation" have been observed with stimulant abuse or misuse. Esketamine nasal spray labeling instructs patients to seek medical attention for new or sudden changes in mood, behavior, thoughts, or feelings, including acting aggressive, angry, or violent. The antipsychotic aripiprazole lists homicidal ideation among rare adverse reactions in adults.
For CCHR, the central issue is what happens after such risks appear in official labeling. Printing a warning does not ensure that a patient has seen it, understood it, or discussed it with a physician. This concern has also entered public policy. A 2026 Tennessee law requires toxicology testing for psychiatric and other drugs following specified violent incidents. CCHR has called for similar laws in every state.
Eastgate concluded, "Drug labeling now contains warnings and adverse-event information that consumers have a right to know about. While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision. A label alone does not ensure informed consent."
Ultimately, CCHR asserts that the issue is not whether every patient will experience these reactions, but whether patients are adequately informed when regulators and manufacturers have identified serious behavioral risks, and whether prescribers are held accountable for warning patients. Consumers should be able to weigh the risks, recognize warning signs, and seek prompt medical advice about concerning changes. Patients should not abruptly stop taking psychiatric drugs; any reduction or discontinuation should be undertaken with medical supervision.
